

<u>MA (EU) number</u>	<u>(Invented) name</u>	<u>Strength</u>	<u>Pharmaceutical Form</u>	<u>Route of Administration</u>	<u>Immediate Packaging</u>	<u>Content (concentration)</u>	<u>Pack size</u>
EU/1/26/2028/001	mCOMBRIAX	-- ¹	Dispersion for injection	Intramuscular use	pre-filled syringe (COC) in a tray	0.32 mL	1 pre-filled syringe
EU/1/26/2028/002	mCOMBRIAX	-- ¹	Dispersion for injection	Intramuscular use	pre-filled syringe (COC) in a tray	0.32 mL	10 pre-filled syringes

--¹ One dose (0.32 mL) contains 31.7 micrograms of total RNA.

mCOMBRIAX is single-stranded, 5'-capped messenger RNAs (mRNAs) produced using a cell-free in vitro transcription from the corresponding DNA template, encoding seasonal influenza haemagglutinin (HA) glycoproteins: A/H1N1, A/H3N2, B/Victoria, and the linked N-terminal domain and receptor-binding domain of the viral spike (S) protein of SARS-CoV-2.

Influenza virus strains and SARS-CoV-2 composition per 0.32 mL dose:

A/Wisconsin/67/2022 (A/H1N1 pdm09)8.3 micrograms RNA
A/Darwin/6/2021 (A/H3N2)8.3 micrograms RNA
B/Austria/1359417/2021 (B/Victoria lineage)8.3 micrograms RNA
SARS-CoV-2 Omicron XBB.1.56.7 micrograms RNA